Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06797336 · ClinicalTrials.gov registry record · Phase 1

A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

A Phase 1 study of Solid Tumor, sponsored by PAQ Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
115
Enrollment target
7
Study locations

NCT06797336 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by PAQ Therapeutics. The registered enrollment target is 115 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (48% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06797336, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by PAQ Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
115 participants
Enrollment target
7
Study locations

Study Summary

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.

Conditions Studied

Solid Tumor

Interventions

  • DRUG PT0253

Study Locations (7)

Tennessee

  • SCRI Lake Mary - Nashville
  • SCRI Oncology Partners - Nashville

Texas

  • New Experimental Therapeutics of San Antonio LLC - San Antonio
  • START - South Texas Accelerated Research Therapeutics, LLC - San Antonio

Massachusetts

  • Dana Farber/Massachusetts General Hospital, Inc - Boston

Utah

  • START Mountain Region - West Valley City

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2024-12-19
Est. Completion 2027-06-16
Phase Phase 1

Sponsor

PAQ Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06797336

The ClinicalTrials.gov registry entry for NCT06797336 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (48% lower). The listed sponsor is PAQ Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PT0253 is the first listed.

NCT06797336 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Tennessee, Texas, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06797336 about?

NCT06797336 is a clinical study titled "A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors". The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherap...

What is the current status of trial NCT06797336?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2024-12-19. Estimated completion is 2027-06-16.

What conditions does trial NCT06797336 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT06797336?

The interventions under investigation include: PT0253 (DRUG).

Who is sponsoring clinical trial NCT06797336?

This trial is sponsored by PAQ Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06797336 being conducted?

This trial has 7 study locations across Massachusetts, Tennessee, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.